US 12,385,903 B2
RP182 compositions and methods
Patrick Soon-Shiong, Culver City, CA (US); and Kayvan Niazi, Culver City, CA (US)
Assigned to NantBio, Inc., Culver City, CA (US)
Appl. No. 17/263,409
Filed by NantBio, Inc., Culver City, CA (US)
PCT Filed Aug. 26, 2019, PCT No. PCT/US2019/048181
§ 371(c)(1), (2) Date Jan. 26, 2021,
PCT Pub. No. WO2020/046835, PCT Pub. Date Mar. 5, 2020.
Claims priority of provisional application 62/723,411, filed on Aug. 27, 2018.
Prior Publication US 2021/0293789 A1, Sep. 23, 2021
Int. Cl. G01N 33/53 (2006.01); G01N 33/50 (2006.01)
CPC G01N 33/5055 (2013.01) [G01N 2510/00 (2013.01)] 10 Claims
 
1. A method of producing a pharmaceutical agent, comprising:
identifying a synthetic peptide as a selective binder to carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206;
quantifying an affinity of the synthetic peptide to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206;
evaluating a variant of a fragment of the synthetic peptide to establish an amino acid substitution;
preparing a modified synthetic peptide to include the amino acid substitute to thereby produce the pharmaceutical agent, wherein substituting the amino acid increases the affinity to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206; and
contacting a plurality of macrophages with the modified synthetic peptide that includes the amino acid substitute, thereby inducing phagocytic activity and/or inducing of apoptosis in M2 macrophages; and
wherein the pharmaceutical agent is an RP182 analog selected from the group consisting of SEQ ID NO:2-SEQ ID NO:28.